胸腺肽治疗小儿反复呼吸道感染55例临床分析

The clinical analysis of thymic peptide in children with recurrent respiratory tract infection:on 55 cases report

目的分析胸腺肽用于小儿反复呼吸道感染的临床疗效。方法将110例小儿反复呼吸道感染患者分为观察组和对照组各55例。2组均给予对症支持和常规治疗,观察组加用胸腺肽治疗。治疗后比较2组临床疗效、静脉血免疫球蛋白含量并观察不良反应。结果观察组总有效率为94.55%高于对照组的81.82%,差异有统计学意义(P<0.05)。2组治疗后静脉血免疫球蛋白IgA、IgM、IgG水平明显高于治疗前,且观察组低于对照组,差异均有统计学意义(P<0.05)。2组均未发现明显不良反应。结论胸腺肽治疗小儿反复呼吸道感染疗效好,能增加免疫功能,安全、可靠。

Objective To analyze the effect of thymic peptide in children with recurrent respiratory tract infection.Methods 110 cases children with recurrent respiratory tract infection were randomly divided into observation group and control group,each of 55 cases.Two groups were given symptomatic support and general treatment,observation group were treated with thymic peptide.After treatment,compared the clinical efficacy,intravenous immune globulin content of blood and adverse reaction of two groups.Results The total effective rate of observation group（94.55%） was significantly higher than that of control group（81.82%）（P0.05）.After treatment,venous immunoglobulin IgA,IgM,IgG were significantly higher than those before treatment,and were lower than those of control group,the difference were statistically significant（P0.05）.No found significant adverse reaction of two groups.Conclusion Thymic peptide in children with recurrent respiratory tract infection is effective,can increase immune function,safe and reliable.